Discover what Novelmab is, how its dual targeting of PD‑1 and a tumor‑associated antigen works, and why this next‑generation bispecific antibody is generating buzz in oncology for potentially overcoming resistance to standard immunotherapy in solid tumors.
Discover how NEO-201, an investigational monoclonal antibody, targets tumor-associated neoepitopes and abnormal O-glycans to enhance antibody-dependent cellular cytotoxicity (ADCC), reshape the tumor microenvironment, and potentially synergize with checkpoint inhibitors in solid tumor treatment.